Company intelligence / Profile preview

Li Shuai

Shanghai, Shanghai Municipality, Chinashuaili8.github.io ↗

Ownership: Private
Development stage: Other

Overview

SIMR is developing a novel drug to alleviate severe pain in cancer patients, addressing the limitations of morphine such as tolerance and reduced efficacy over time. The company is also working on an anti-cancer drug with broad-spectrum activity. Their lead pain-relief candidate is undergoing clinical trials in China and Australia, with commercialization expected several years out[2].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Li Shuai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Li Shuai.

Explore the full profile